天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Biomolecules >>article
Biomolecules

Biomolecules

IF: 4.79
Download PDF

Efavirenz: History, Development and Future.

Published:31 December 2022 DOI: 10.3390/biom13010088 PMID: 36671473
Bárbara Costa, Nuno Vale

Abstract

Efavirenz (Sustiva?) is a first-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the spread of HIV. In 1998, the FDA authorized efavirenz for the treatment of HIV-1 infection. Patients formerly required three 200 mg efavirenz capsules daily, which was rapidly updated to a 600 mg tablet that only required one tablet per day. However, when given 600 mg once daily, plasma efavirenz concentrations were linked not only to poor HIV suppression but also to toxicity. Clinical data suggested that the standard dose of efavirenz could be reduced without compromising its effectiveness, resulting in a reduction in side effects and making the drug more affordable. Therefore, ENCORE1 was performed to compare the efficiency and safeness of a reduced dose of efavirenz (400 mg) with the standard dose (600 mg) plus two NRTI in antiretroviral-na?ve HIV-infected individuals. Nowadays, due to the emergence of integrase strand transfer inhibitors (INSTIs), some consider that it is time to stop using efavirenz as a first-line treatment on a global scale, in the parts of the world where that is possible. Efavirenz has been a primary first-line antiviral drug for more than 15 years. However, at this moment, the best use for efavirenz could be for pre-exposure prophylaxis (PrEP) and repurposing in medicine.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Efavirenz 154598-52-4 C14H9ClF3NO2 530 suppliers $25.00-$2400.00

Similar articles

IF:2.2

Anticancer Properties of Some Selected Plant Phenolic Compounds: Future Leads for Therapeutic Development

Neural Regeneration Research N. Maheshwari , M.C. Sharma,etc Published: 17 October 2023
IF:0

[Theophylline--past present and future].

Neural Regeneration Research R Wettengel,etc Published: 1 May 1998
IF:5.9

A BRIEF HISTORY OF TESTOSTERONE

Neural Regeneration Research ERICA R. FREEMAN, DAVID A. BLOOM,etc Published: 1 February 2001